The global oncology biosimilars market exhibited strong growth during 2015-2020.
Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include targeted therapies as well as immunotherapies. These drugs are produced using living organisms, including bacteria, yeast, and animal or plant cells, and require complex manufacturing processes and long development time. As a result, the cost of these drugs is relatively higher, which adds to the expense of cancer treatment. To lower the price of treatment, the interest in the development of biosimilars of branded oncology biologics has been increasing. These biosimilars are highly similar to the reference biologics in terms of effectiveness and safety and can help in significantly reducing the expenditure on cancer treatment due to their lower cost.
Over the years, the rising number of geriatric population and environmental degradation have increased the prevalence of cancer across the globe. These factors, along with the inflating cost of cancer care, have increased the burden on healthcare systems worldwide. Consequently, governing authorities in numerous countries are promoting the uptake of biosimilars as a cost-containment measure. For instance, the United States Food and Drug Administration (USFDA) has developed information materials for physicians and patients to educate them about biosimilars. Apart from this, the availability of affordable medication has also been associated with earlier and wider therapy use as well as improved patient access. Besides this, oncology biosimilars can also increase industry competition, owing to which they have the potential to drive down the prices of biological drugs further. Some of the other growth-inducing factors for the market include approaching patent expiries of branded biologics and increasing research and development (R&D) activities by biosimilar manufacturers. Looking forward, the analyst expects the global oncology biosimilars market to grow at a CAGR of around 17% during the forecast period (2021-2026).
Report Coverage: Historical, Current and Future Market Trends
Market Breakup by Drug Type: Monoclonal Antibody Immunomodulators G-CSF Hematopoietic Agents Others
Market Breakup by Cancer Type: Lung Cancer Colorectal Cancer Cervical Cancer Breast Cancer Kidney Cancer Stomach Cancer Brain Cancer Others
Market Breakup by Distribution Channel: Hospital Pharmacies Online Pharmacies Retail Pharmacies Others
Market Breakup by Region: Europe Asia Pacific North America Middle East and Africa Latin America
Competitive Landscape: The report has also analyzed the competitive landscape of the market with some of the key players being Biocon, Celltrion Inc., Dr. Reddy’s Laboratories, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Mylan, F Hoffmann-La Roche, etc.
Key Questions Answered in This Report: How has the global oncology biosimilars market performed so far and how will it perform in the coming years? What are the key regional markets in the global oncology biosimilars industry? What has been the impact of COVID-19 on the global oncology biosimilars industry? What is the breakup of the market based on the drug type? What is the breakup of the market based on the cancer type? What is the breakup of the market based on the distribution channel? What are the various stages in the value chain of the global oncology biosimilars industry? What are the key driving factors and challenges in the global oncology biosimilars industry? What is the structure of the global oncology biosimilars industry and who are the key players? What is the degree of competition in the global oncology biosimilars industry?
Our reports have been used by over 10K customers, including:
The biosimilar market reached a value of US$ 7.7 Billion in 2020. This market is currently being driven by a number of factors such as patent expires of blockbuster biological drugs, lower prices, rising prevalence of chronic diseases, and cost-saving initiatives from governments and third-party payers. Catalyzed by these factors, the market...
The Global Microbiome Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Microbiome partnering deals Disclosed headlines, upfronts, milestones and royalties by...
175 pages •
By The Business Research Company
• Jun 2021
Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences, and Roche Holdings AG The global enzymes market is expected to grow from $7.81 billion in 2020 to $8.9 billion in 2021 at a compound annual growth rate (CAGR)...
The Global Stem Cell Partnering Terms and Agreements 2010-2021 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in stem cell partnering Deal terms analysis Partnering agreement structure Partnering...
Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1 or Type I Interferon Receptor 1 or IFNAR1) - Drugs in Development, 2021 Summary Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1...
703 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• Mar 2021
Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having a direct effect on disease treatment. APIs are synthesized by chemical synthesis, fermentation, biotechnological methods or enhanced from the natural source. According to the analysis,...
120 pages •
By Infiniti Research Limited
• Jun 2021
Global Biosimilars Market 2021-2025 The analyst has been monitoring the biosimilars market and it is poised to grow by $ 31.40 bn during 2021-2025, progressing at a CAGR of 24.77% during the forecast period. Our report on the biosimilars market provides a holistic analysis, market size and forecast, trends, growth drivers,...
The Global Biologics CDMO Market was valued at USD 9.93 billion in 2020 and is expected to reach USD 18.63 billion by 2026, registering a CAGR of 10.87% during the forecast period (2021-2026). The CMO/CDMO service sector is uniquely positioned to address some of the challenges that drug developers are facing amid the COVID-19 pandemic....
Apoptosis Regulator BAX - Drugs In Development, 2021 Summary Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Apoptosis regulator BAX or bcl-2-like protein 4 is a protein is encoded by the BAX gene. It accelerates programmed cell death by antagonizing the apoptosis repressor BCL2....
Cause-Specific Mortality Rate
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.